Haisco Out-Licenses Global Ex-China Rights for Bronchiectasis Therapy to Italy’s Chiesi Farma
publication date: Nov 20, 2023
Chengdu Haisco Pharma out-licensed global (ex-Greater China) rights for its dipeptidyl peptidase 1 (DPP1) inhibitor, a proposed therapy for bronchiectasis, to Chiesi Farmaceutici of Parmi, Italy. HSK31858 is an oral, highly selective small molecule DPP1 inhibitor developed by Haisco with the potential to be an anti-inflammatory agent in bronchiectasis. Haisco is currently conducting a China Phase II trial of HSK31858 for the indication. Chiesi will have rights to develop, manufacture and commercialize HSK31858 outside greater China. The deal calls for an upfront payment, milestones and royalties, though specific amounts were not disclosed. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.